News

U.S. Institute of Peace offen für Nominierungen für den „Women Building Peace Award” 2023

by

WASHINGTON, 5. Juni 2023 /PRNewswire/ — Das United States Institute of Peace (USIP) gibt bekannt, dass der „Women Building Peace Award” 2023 für Nominierungen geöffnet ist. Die prestigeträchtige jährliche Auszeichnung ehrt mutige Frauen aus der Zivilgesellschaft, die in Ländern, die von gewaltsamen Konflikten betroffen sind, Frieden stiften. Unzählige Frauen riskieren ihr Leben, um Frieden in … Read more

Lunit and Capio S:t Göran Hospital Collaborate to Address Radiologist Shortage with AI-Powered Mammography Analysis

by

– Lunit and Sweden’s largest private hospital pioneering a new approach to combine radiologists’ expertise with AI SEOUL, South Korea, June 5, 2023 /PRNewswire/ — Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer diagnostic solutions, today announced the signing of a supply and license agreement with Capio S:t Göran Hospital, Stockholm, Sweden. Under the agreement, … Read more

PhenomeX to Participate in Antibody Engineering & Therapeutics Europe 2023

by

Company to feature its recently launched Beacon Select™ technology for antibody discovery and cell line development EMERYVILLE, Calif., June 5, 2023 /PRNewswire/ — PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced its participation in the Antibody Engineering & Therapeutics (AE&T) Europe 2023 from 6-8 June 2023 at the Postillion Hotel Amsterdam. AE&T is … Read more

PhenomeX nimmt an der Antibody Engineering & Therapeutics Europe 2023 teil

by

Das Unternehmen stellt seine kürzlich eingeführte Beacon Select™-Technologie für die Entdeckung von Antikörpern und die Entwicklung von Zelllinien vor  EMERYVILLE, Kalifornien, 5. Juni 2023 /PRNewswire/ — PhenomeX Inc. (Nasdaq: CELL), das Unternehmen für funktionelle Zellbiologie, gab heute seine Teilnahme an der Antibody Engineering & Therapeutics (AE&T) Europe 2023 vom 6.-8. Juni 2023 im Postillion Hotel … Read more

Edward W. Marple, A.B. (Harvard), MBA (Virginia), joins Paraza Pharma as Executive Vice-President, Development

by

MONTREAL, June 5, 2023 /PRNewswire/ – Paraza Pharma is pleased to announce the appointment of Edward W. (Ted) Marple, A.B. (Harvard), MBA (Virginia) as Executive Vice-President, Development.  Mr. Marple, who has more than 20 years of experience as a senior executive with broad skill sets across clinical development, IP protection, manufacturing, operations, company and product … Read more

Gencurix Announces Clinical Research Results At ASCO 2023 Demonstrating Outstanding Performance of GenesWell BCT, the Company’s Breast Cancer Prognostic Test, Compared to Global Best-Selling Test, OncotypeDX

by

SEOUL, South Korea, June 4, 2023 /PRNewswire/ — Gencurix (KOSDAQ #229000), a leading provider of cancer molecular diagnostics, announced the release of clinical research results directly comparing the accuracy of its breast cancer prognostic test, GenesWell BCT, with Oncotype DX, the globally top-selling test, confirming its outstanding performance. The study, presented at the American Society … Read more

Edward W. Marple, AB (Harvard), MBA (Virginia), se une a Paraza Pharma como vicepresidente ejecutivo de Desarrollo

by

MONTREAL, 5 de junio de 2023 /PRNewswire/ — Paraza Pharma se complace en anunciar el nombramiento de Edward W. (Ted) Marple, A.B. (Harvard), MBA (Virginia) como vicepresidente ejecutivo de Desarrollo. Marple, que tiene más de 20 años de experiencia como ejecutivo sénior con un amplio conjunto de habilidades en desarrollo clínico, protección de propiedad intelectual, … Read more

Edward W. Marple, A.B. (Harvard), MBA (Virginia), joins Paraza Pharma as Executive Vice-President, Development

by

MONTREAL, June 5, 2023 /PRNewswire/ — Paraza Pharma is pleased to announce the appointment of Edward W. (Ted) Marple, A.B. (Harvard), MBA (Virginia) as Executive Vice-President, Development.  Mr. Marple, who has more than 20 years of experience as a senior executive with broad skill sets across clinical development, IP protection, manufacturing, operations, company and product … Read more

Edward W. Marple, A.B. (Harvard), MBA (Virginia), stößt als Executive Vice-President, Entwicklung, zu Paraza Pharma

by

MONTREAL, 5. Juni 2023 /PRNewswire/ — Paraza Pharma freut sich, die Ernennung von Edward W. (Ted) Marple, A.B. (Harvard), MBA (Virginia) zum Executive Vice-President, Entwicklung, bekannt zu geben.  Herr Marple verfügt über mehr als 20 Jahre Erfahrung als Führungskraft mit breit gefächerten Kompetenzen in den Bereichen klinische Entwicklung, Schutz des geistigen Eigentums, Herstellung, Betrieb, Unternehmens- … Read more

Liminal BioSciences geeft R&D-update

by

LMNL6326 is genomineerd als belangrijkste preklinische kandidaat voor het OXER1-antagonisten ontwikkelprogramma, gericht op de behandeling van door eosinofielen veroorzaakte ziekten Vooruitgang van klinische studieaanvraag (clinical trial application – CTA) die preklinische studies van LMNL6511 mogelijk maakt ter ondersteuning van CTA-aanvraag voor Fase 1 klinische studie in de tweede helft van 2023 Inzichten verkregen uit preklinische in-vivostudies … Read more